Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | De-China Supply Chain · FC-BGA Geopolitics · MLCC Strategic Asset / 2026-06-05 Research
  • [Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Supply Constraints · Multi-Year LTA · Shareholder Returns / 2026-04-24 Research
  • [Research] Samsung SDI (006400) – iM Securities | Surging AIDC ESS Demand · US Regulatory Tailwinds · Valuation Assessment / 2026-04-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – Kyobo Securities | AI Server Demand · High-Value Mix · Structural Profitability / 2026-07-31 Research
  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research
  • [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | NAND Pricing · Fab Utilization · Earnings Upgrades / 2026-01-07 Research

[Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Long-term Exclusive Contracts · 2029 Target EPS · Structural ASP Hikes / 2026-06-01

Posted on June 1, 2026August 24, 2026 By ksb220805@gmail.com

Brokerage : Mirae Asset Securities

Analyst : Junseo Park (park.junseo@miraeasset.com)

Investment Rating : BUY (Maintained)

Target Price : KRW 2,800,000 (Raised)

Core Momentum : Application of 2029 forward valuation backed by sold-out substrate capacity and multi-year exclusive contracts, alongside structural ASP increases for substrates (+20%) and MLCCs (+10%) from 2027

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY (Maintained) / Target Price KRW 2,800,000 (Raised by +115% from KRW 1,300,000) (Closing price KRW 2,127,000 as of May 29, 2026; upside potential 31.6%)
  • Valuation Methodology: Shifted the valuation benchmark base from 2028 to 2029, applying a Target P/E multiple of 30x (historical up-cycle average) to 2029(E) EPS of KRW 93,242. This forward valuation is justified by multi-year exclusive agreements that secure long-term revenue visibility.
  • Medium-Term Growth Projections (2026F–2030F): Revenue CAGR of +24.6%, Operating Profit CAGR of +61.3%
  • Key Financial Metrics & Forecast:
    • Revenue (KRW): 2024 KRW 10.294 Trillion → 2025 KRW 11.314 Trillion → 2026(E) KRW 13.520 Trillion → 2027(E) KRW 16.465 Trillion → 2028(E) KRW 22.238 Trillion
    • Operating Profit (KRW): 2024 KRW 735.0 Billion → 2025 KRW 913.0 Billion → 2026(E) KRW 1.562 Trillion → 2027(E) KRW 3.408 Trillion → 2028(E) KRW 5.870 Trillion
    • Operating Profit Margin (OPM): 2024 7.1% → 2025 8.1% → 2026(E) 11.6% → 2027(E) 20.7% → 2028(E) 26.4%
    • Net Profit (Controlling) (KRW): 2024 KRW 679.0 Billion → 2025 KRW 706.0 Billion → 2026(E) KRW 1.313 Trillion → 2027(E) KRW 2.827 Trillion → 2028(E) 4.925 Trillion
    • EPS (KRW): 2024 KRW 8,752 → 2025 KRW 9,099 → 2026(E) KRW 16,914 → 2027(E) KRW 36,428 → 2028(E) KRW 63,466
    • Valuation Multiples (PER / PBR / ROE):
      • 2024: PER 14.1x, PBR 1.1x, ROE 8.2%
      • 2025: PER 28.0x, PBR 2.3x, ROE 7.7%
      • 2026(E): PER 125.8x, PBR 17.0x, ROE 13.0%
      • 2027(E): PER 58.4x, PBR 13.4x, ROE 23.5%
      • 2028(E): PER 33.5x, PBR 12.6x, ROE 35.9%
  • 2026 Annual Forecast vs. Consensus:
    • 2026 Operating Profit estimated at KRW 1.562 Trillion (vs. consensus of KRW 1.589 Trillion)

🚀 2. [Market Opportunities & Business Outlook]

  • AI Bottleneck Shift & Multi-Year Exclusive Contracts:
    • Global hardware bottlenecks in AI infrastructure are rapidly expanding into substrates and MLCCs.
    • Complete sell-out of substrate capacity has prompted an influx of customer prepayments, co-investment funding, and multi-year exclusive agreements, initiating a prolonged CAPEX expansion starting in 2026.
    • High-visibility multi-year contracts provide even stronger valuation justification than the 2- to 3-year forward valuation precedents seen during past electric vehicle and battery up-cycles.
  • ASP Increases & CAPEX Upgrades:
    • Substrates (FC-BGA): Upward CAPEX revisions for AI server/network applications alongside a +20% ASP increase modeled from 2027.
    • AI Capacitors (MLCC + Si-Cap): +10% blended MLCC ASP increase modeled for 2027, with server-grade MLCC price hikes outpacing commodity lines, further amplified by rapid demand expansion for silicon capacitors.
  • Operational Supply-Demand Indicators:
    • Global lead times for certain MLCC lines have lengthened from the typical 10 weeks to 20–24 weeks.
    • Company inventory cycles have dropped to 4 weeks (below the typical 6-week baseline), driving aggressive client acceptance of LTAs and price hikes to secure preemptive allocation.

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electro-Mechanics not merely as a passive component maker exposed to consumer tech fluctuations, but as an industry-leading hardware platform capturing long-term growth visibility through multi-year exclusive agreements across critical AI bottlenecks (FC-BGA and AI capacitors). This perspective justifies a structural valuation shift toward 2029(E) EPS (KRW 93,242 at 30x P/E), supported by substrate line sell-outs, client-backed co-investments, and a multi-year earnings CAGR (+61.3% in operating profit) that eclipses historical cycle peaks.

To evaluate whether this investment thesis unfolds as anticipated, key verification checkpoints include the formal disclosure of multi-year exclusive FC-BGA contracts with customer funding, the execution of modeled 2027 ASP increases (+20% for substrates and +10% for MLCCs), the persistence of tight 4-week inventory cycles alongside elongated lead times, and the pace of commercial revenue recognition from silicon capacitors. Progress on these fronts can be tracked via upcoming quarterly earnings announcements, investor relations presentations, and official regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01
Next Post: [Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02

Related Posts

  • [Research] Hanwha Ocean (042660) – Hanwha | Merchant Margin Surprise · High-Price Mix Expansion · Special Ship Fixed-Cost Absorption / 2026-04-28 Research
  • [Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | Supply Tightness · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | NAND Pricing · Fab Utilization · Earnings Upgrades / 2026-01-07 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 6 Groundbreaking Visibility · Labor Negotiation · Rockville Revenue Recognition / 2026-04-02 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08 Research
  • [Research] Samsung SDI (006400) – Shinhan Securities | Profit Turnaround · ESS Margin Support · North America LFP Ramp-up / 2026-07-20 Research
  • [Research] LIG D&A (079550) – Shinhan Securities | 1Q26 Surprise · Demand Surge · Long-term Compounding / 2026-05-08 Research
  • [Research] Samsung Electro-Mechanics (009150) – DS Investment & Securities | Price Hikes Ahead · Shortage Cycle · 2027F Peer Multiple / 2026-05-04 Research
  • [Research] Samsung SDI (006400) – Daishin Securities | Earlier Turnaround · North America ESS Expansion · LFP Order Pipeline / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | AI Server Demand · Memory ASP · High-Value Product Mix / 2026-01-30 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme